Search Results | Blood | American Society of Hematology

1-20 of 488

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience

Divaya Bhutani, MD, Vikram Premkumar, MD, Shayan Shirazayan, MD, Andrew Bomback, MD, Jai Radhakrishnan, MD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 5565.

DOI: https://doi.org/10.1182/blood-2019-128455

Published: 2019

Journal Articles

Prevalence of Monoclonal Gammopathy of Undetermined Significance in a Large Population with Annual Physical Examination in Beijing, China

Jinuo Wang, MD, Jian-Hua Han, Yue-lun Zhang, Xin-xin Cao, Dao-Bin Zhou, Teng-da Xu, Wei Su, Jian Li, MD

Blood (2019) 134 (Supplement_1): 5519.

DOI: https://doi.org/10.1182/blood-2019-124715

Published: 2019

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

DOI: https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Pamela S. Becker, MD PhD, Kim Quach, Ted A Gooley, PhD, Edward N. Libby, III, MD, Andrew J. Cowan, MD, David G. Coffey, MD, Bret Gary Degraaff, BS, Cody Hammer, Jin Dai, PhD, Sylvia Chien, Josh Epworth, ARNP, Gabrielle A Zecha, PA-C, Heather Smith, PA-C, Timothy S Martins, PhD

Blood (2019) 134 (Supplement_1): 1902.

DOI: https://doi.org/10.1182/blood-2019-130990

Published: 2019

Journal Articles

Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease

Surbhi Sidana, MD, David L Murray, MD PhD, Surendra Dasari, PhD, Ronald S. Go, MD, Maria Alice Willrich, PhD, Melissa Snyder, PhD, Mindy Kohlhagen, John A. Lust, MD PhD, Eli Muchtar, MD, Taxiarchis Kourelis, MD, Shaji K. Kumar, MD, Angela Dispenzieri, MD, Morie A. Gertz, MD

Blood (2019) 134 (Supplement_1): 3510.

DOI: https://doi.org/10.1182/blood-2019-121712

Published: 2019

Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD

Blood (2019) 134 (Supplement_1): 1853.

DOI: https://doi.org/10.1182/blood-2019-128760

Published: 2019

Journal Articles

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Eftathios Kastritis, Maria Gavriatopoulou, MD, Maria Roussou, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioanna Dialoupi, MD, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Foteini Theodorakakou, MD, Asimina Papanikolaou, MD, Erasmia Psimenou, MD, Kimon Stamatelopoulos, MD, Efstathios Manios, MD, Maria Irini Tselegkidi, MD, Argyrios Ntalianis, MD, Stavroula Giannouli, MD PhD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1894.

DOI: https://doi.org/10.1182/blood-2019-128208

Published: 2019

Journal Articles

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Eftathios Kastritis, Nikolaos Kanellias, MD, Foteini Theodorakakou, MD, Erasmia Psimenou, MD, Charikleia Gakiopoulou, MD, Smaragdi Marinaki, Maria Roussou, MD, Maria Gavriatopoulou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1776.

DOI: https://doi.org/10.1182/blood-2019-126385

Published: 2019

Journal Articles

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Danny Luan, BS, MPH, Koen Van Besien, MD PhD, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2019) 134 (Supplement_1): 4579.

DOI: https://doi.org/10.1182/blood-2019-127723

Published: 2019

Journal Articles

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Sandro Bräunig, MSc, Dimitra Zacharaki, PhD, Hongzhe Li, PhD, Hooi Ching Lim, PhD, Stefan Lang, PhD, Thoas Fioretos, MD PhD Prof., Stefan Scheding, MD

Blood (2019) 134 (Supplement_1): 4373.

DOI: https://doi.org/10.1182/blood-2019-128024

Published: 2019

Journal Articles

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Faye Amelia Sharpley, BA MA MSc MBBChir FRCPath, Hannah Victoria Giles, FRCPath, MRCP, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Carol J Whelan, Philip N Hawkins, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 4375.

DOI: https://doi.org/10.1182/blood-2019-128175

Published: 2019

Journal Articles

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Marion Eveillard, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Eric L Smith, MD PhD, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X Lu, MD PhD, Neha Korde, MD, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 4377.

DOI: https://doi.org/10.1182/blood-2019-128938

Published: 2019

Journal Articles

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Shayna Sarosiek, Vaishali Sanchorawala, MD, Mariateresa Fulcinti, Allison P. Jacob, Nikhil C. Munshi, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 4353.

DOI: https://doi.org/10.1182/blood-2019-131863

Published: 2019

Journal Articles

Glycosylationof Immunoglobulins Determine Bone Loss in Multiple Myeloma

Marita Westhrin, Vlado Kovcic, Albert Bondt, Stephanie Holst, Zejian Zhang, Anders Sundan, PhD, Tobias S. Slørdahl, Anders Waage, MD PhD, Manfred Wuhrer, Therese Standal

Blood (2019) 134 (Supplement_1): 4324.

DOI: https://doi.org/10.1182/blood-2019-122542

Published: 2019

Journal Articles

Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4386.

DOI: https://doi.org/10.1182/blood-2019-130771

Published: 2019

Journal Articles

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Jihad Aljabban, MMSc, BA, David Chen, BS, Francesca Cottini, MD, Saad Syed, BS, Nabeal Aljabban, BS, Sharjeel Syed, BS, Tiffany Hughes, PhD, David Feldman, BS, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2019) 134 (Supplement_1): 4395.

DOI: https://doi.org/10.1182/blood-2019-129699

Published: 2019

Journal Articles

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

Pinelopi I Artemaki, BSc, Aristea-Maria Papanota, MD, Paraskevi Karousi, BSc, Christine Liacos, MSc, Christos K. Kontos, PhD, Dimitris Patseas, BSc, Maria-Alexandra Papadimitriou, BSc, Evangelos Eleutherakis-Papaiakovou, MD, Margaritis Avgeris, PhD, Nikolaos Kanellias, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Ioanna Dialoupi, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Meletios A. Dimopoulos, MD, Andreas Scorilas, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 5529.

DOI: https://doi.org/10.1182/blood-2019-129218

Published: 2019

Journal Articles

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

Saurabh Mishra, MD DNB, Ashok K Vaid, MDDM, Nitin Sood, MDFRCPath,MRCP, Manorama Bhargava, Bhuvan Chugh, DNB, Roshan Dixit, MD, Amrita Ramaswami, MDDM, Devender Sharma, MD

Blood (2019) 134 (Supplement_1): 5559.

DOI: https://doi.org/10.1182/blood-2019-125752

Published: 2019

Journal Articles

The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies

Alba Rodríguez García, María Linares, PhD, Nicolas Mennesson, Alfredo Pérez-Revilla, Ricardo Sanchez, PhD MD, Alejandra Leivas, PhD BS, MSc, Rafael Alonso Fernández, MD, Edith Bigot-Corbel, PhD, Sylvie Hermouet, Joaquin Martinez-Lopez, MD PhD

Blood (2019) 134 (Supplement_1): 5560.

DOI: https://doi.org/10.1182/blood-2019-126549

Published: 2019

Journal Articles

Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018

Laura L Hester, PhD MSc, Dina M Gifkins, PhD MPH, Kevin M Bellew, MS, MA, Jessica Vermeulen, MD PhD, Jordan M Schecter, MD, Frank J DeFalco, Brendan M Weiss, MD

Blood (2019) 134 (Supplement_1): 5517.

DOI: https://doi.org/10.1182/blood-2019-124250

Published: 2019

2 3 4 5

NARROW

Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience

Prevalence of Monoclonal Gammopathy of Undetermined Significance in a Large Population with Annual Physical Examination in Beijing, China

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Glycosylationof Immunoglobulins Determine Bone Loss in Multiple Myeloma

Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies

Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only